ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements with these filters
Sudeep Pharma delivered record quarterly revenue led by its Pharma Food Nutrition (PFN) segment, though specialty ingredients face short-term headwinds from the pause of a government rice program.
Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.
Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.
Mr. Sendhil Pani has ceased to be a Senior Management Personnel of Sudeep Pharma Ltd effective October 2, 2026. This follows the completion of his contractual arrangements.
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Limited corrected a clerical error regarding the number of attendees at its Annual General Meeting, updating the count from 45 to 44.
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026. The meeting transacted business including financial statement approval, director appointments, dividend declaration, and ESOP schemes.
Nuvama Crossover Opportunities Funds reduced their stake in Sudeep Pharma Ltd. The promoter field is 'No', indicating a non-promoter equity transaction.
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.
Sudeep Pharma has scheduled a Board meeting for August 4, 2026, to consider and approve the unaudited standalone and consolidated financial results for the June quarter.
Sudeep Pharma Ltd announced a final dividend of ₹1.50 per share. The record date is set for 23 July 2026.
Sudeep Pharma Ltd will hold its 37th AGM on 4 Aug 2026 via video conference. The agenda includes dividend of Rs.1.50 per share and director re‑appointment.
Sudeep Pharma filed its FY 2025-26 Annual Report with BSE, declaring a ₹1.50 final dividend. It reports a market cap of ₹6,693 crore and entry into battery materials.
Sudeep Pharma appointed Mr. Milin Mehta as a Non-Executive Non-Independent Director. The appointment was approved during the board meeting on June 26, 2026.
Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.
Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.
Sudeep Pharma recommended a ₹1.5 per share final dividend for FY 2025-26. The record date is July 24, 2026, with payment scheduled by August 9.
Sudeep Pharma recommended a ₹1.50 per share final dividend for FY 2025-26. The record date is set for July 24, 2026, pending shareholder approval.
Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.
Sudeep Pharma reported a consolidated annual net profit of ₹174.28 Crore for FY2026. The board also recommended a final dividend of ₹1.50 per equity share.
Sudeep Pharma debuted with solid Q2 performance but faced temporary US tariff headwinds. Management is pivoting from pure excipients to high-value specialty ingredients and battery materials via a new Dahej facility.
Sudeep Pharma Ltd scheduled a board meeting for May 21, 2026. Directors will consider audited FY26 financial results and a final dividend recommendation.